Sonoma Pharmaceuticals, Inc. (SNOA)
USD 3.38
(-4.52%)
USD 3.38
(-4.52%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 | 608 Thousand USD | -28.39% |
| 2023 | 849 Thousand USD | -37.89% |
| 2022 | 1.36 Million USD | -48.9% |
| 2021 | 2.67 Million USD | 80.99% |
| 2020 | 1.47 Million USD | 211.16% |
| 2019 | 475 Thousand USD | -14.1% |
| 2018 | 553 Thousand USD | 34.88% |
| 2017 | 410 Thousand USD | 259.65% |
| 2016 | 114 Thousand USD | 31.03% |
| 2015 | 87 Thousand USD | -40.82% |
| 2014 | 147 Thousand USD | -92.4% |
| 2013 | 1.93 Million USD | -40.26% |
| 2012 | 3.23 Million USD | 27.27% |
| 2011 | 2.54 Million USD | 710.51% |
| 2010 | 314 Thousand USD | -6.27% |
| 2009 | 335 Thousand USD | -84.94% |
| 2008 | 2.22 Million USD | -72.47% |
| 2007 | 8.07 Million USD | 948.96% |
| 2006 | 770 Thousand USD | -48.56% |
| 2005 | 1.49 Million USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 522 Thousand USD | -20.31% |
| 2024 Q3 | 385 Thousand USD | -26.25% |
| 2024 Q4 | 608 Thousand USD | 57.92% |
| 2024 FY | 608 Thousand USD | -28.39% |
| 2024 Q1 | 655 Thousand USD | -22.85% |
| 2023 FY | 849 Thousand USD | -37.89% |
| 2023 Q3 | 486 Thousand USD | -37.21% |
| 2023 Q2 | 774 Thousand USD | -18.7% |
| 2023 Q4 | 849 Thousand USD | 74.69% |
| 2023 Q1 | 952 Thousand USD | -30.36% |
| 2022 FY | 1.36 Million USD | -48.9% |
| 2022 Q4 | 1.36 Million USD | 12.98% |
| 2022 Q3 | 1.21 Million USD | -18.57% |
| 2022 Q2 | 1.48 Million USD | -38.82% |
| 2022 Q1 | 2.42 Million USD | -9.2% |
| 2021 Q3 | 1.98 Million USD | -1.74% |
| 2021 Q2 | 2.01 Million USD | 4.46% |
| 2021 FY | 2.67 Million USD | 80.99% |
| 2021 Q1 | 1.93 Million USD | 30.58% |
| 2021 Q4 | 2.67 Million USD | 35.03% |
| 2020 Q3 | 1.09 Million USD | -17.63% |
| 2020 FY | 1.47 Million USD | 211.16% |
| 2020 Q1 | 1.58 Million USD | 233.05% |
| 2020 Q4 | 1.47 Million USD | 34.61% |
| 2020 Q2 | 1.33 Million USD | -15.74% |
| 2019 Q3 | 204 Thousand USD | -35.85% |
| 2019 FY | 475 Thousand USD | -14.1% |
| 2019 Q1 | 478 Thousand USD | -13.56% |
| 2019 Q2 | 318 Thousand USD | -33.47% |
| 2019 Q4 | 475 Thousand USD | 132.84% |
| 2018 Q2 | 446 Thousand USD | -14.23% |
| 2018 FY | 553 Thousand USD | 34.88% |
| 2018 Q4 | 553 Thousand USD | 48.66% |
| 2018 Q3 | 372 Thousand USD | -16.59% |
| 2018 Q1 | 520 Thousand USD | 26.83% |
| 2017 FY | 410 Thousand USD | 259.65% |
| 2017 Q4 | 410 Thousand USD | 583.33% |
| 2017 Q3 | 60 Thousand USD | -23.08% |
| 2017 Q2 | 78 Thousand USD | 18.18% |
| 2017 Q1 | 66 Thousand USD | -42.11% |
| 2016 FY | 114 Thousand USD | 31.03% |
| 2016 Q2 | - USD | -100.0% |
| 2016 Q1 | 35 Thousand USD | -59.77% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q4 | 114 Thousand USD | 0.0% |
| 2015 Q3 | 6000.00 USD | -25.0% |
| 2015 Q2 | 8000.00 USD | -87.5% |
| 2015 Q1 | 64 Thousand USD | -56.46% |
| 2015 Q4 | 87 Thousand USD | 1350.0% |
| 2015 FY | 87 Thousand USD | -40.82% |
| 2014 Q2 | 1.09 Million USD | -19.29% |
| 2014 Q4 | 147 Thousand USD | 200.0% |
| 2014 Q1 | 1.35 Million USD | -30.08% |
| 2014 Q3 | 49 Thousand USD | -95.51% |
| 2014 FY | 147 Thousand USD | -92.4% |
| 2013 Q1 | 2.92 Million USD | -9.76% |
| 2013 Q4 | 1.93 Million USD | 24.2% |
| 2013 Q3 | 1.55 Million USD | -39.35% |
| 2013 Q2 | 2.56 Million USD | -12.11% |
| 2013 FY | 1.93 Million USD | -40.26% |
| 2012 Q1 | 2.9 Million USD | 14.3% |
| 2012 FY | 3.23 Million USD | 27.27% |
| 2012 Q4 | 3.23 Million USD | 0.15% |
| 2012 Q3 | 3.23 Million USD | 26.67% |
| 2012 Q2 | 2.55 Million USD | -12.24% |
| 2011 FY | 2.54 Million USD | 710.51% |
| 2011 Q4 | 2.54 Million USD | 0.51% |
| 2011 Q3 | 2.53 Million USD | 43.46% |
| 2011 Q1 | 1.76 Million USD | 462.42% |
| 2011 Q2 | 1.76 Million USD | -0.06% |
| 2010 Q2 | 207 Thousand USD | -15.16% |
| 2010 Q4 | 314 Thousand USD | 69.73% |
| 2010 Q3 | 185 Thousand USD | -10.63% |
| 2010 FY | 314 Thousand USD | -6.27% |
| 2010 Q1 | 244 Thousand USD | -27.16% |
| 2009 Q2 | 1.27 Million USD | -27.68% |
| 2009 Q4 | 335 Thousand USD | -56.83% |
| 2009 FY | 335 Thousand USD | -84.94% |
| 2009 Q1 | 1.75 Million USD | -21.04% |
| 2009 Q3 | 776 Thousand USD | -38.9% |
| 2008 Q1 | 7.56 Million USD | -6.33% |
| 2008 Q2 | 2.89 Million USD | -61.79% |
| 2008 Q3 | 2.49 Million USD | -13.84% |
| 2008 Q4 | 2.22 Million USD | -10.72% |
| 2008 FY | 2.22 Million USD | -72.47% |
| 2007 FY | 8.07 Million USD | 948.96% |
| 2007 Q3 | 8.1 Million USD | 75.02% |
| 2007 Q2 | 4.62 Million USD | 0.0% |
| 2007 Q4 | 8.07 Million USD | -0.28% |
| 2006 Q4 | 770 Thousand USD | 0.0% |
| 2006 FY | 770 Thousand USD | -48.56% |
| 2005 Q4 | 1.49 Million USD | 0.0% |
| 2005 FY | 1.49 Million USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | 540.94 Million USD | 99.888% |
| Theratechnologies Inc. | 58.96 Million USD | 98.969% |
| Safety Shot Inc | 1.54 Million USD | 60.748% |
| Cosmos Health Inc. | 12.42 Million USD | 95.106% |
| Cronos Group Inc. | 2.53 Million USD | 76.062% |
| Ironwood Pharmaceuticals, Inc. | 715.53 Million USD | 99.915% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | 98.326% |
| Organogenesis Holdings Inc. | 119.35 Million USD | 99.491% |
| Universe Pharmaceuticals INC | 5.48 Million USD | 88.91% |
| ProPhase Labs, Inc. | 21.38 Million USD | 97.156% |
| Dynavax Technologies Corporation | 256.91 Million USD | 99.763% |
| Radius Health, Inc. | 365.31 Million USD | 99.834% |
| China SXT Pharmaceuticals, Inc. | 2.64 Million USD | 77.035% |
| Alvotech | 1.07 Billion USD | 99.943% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | 7.557% |
| Alpha Teknova, Inc. | 30.45 Million USD | 98.004% |
| Intra-Cellular Therapies, Inc. | 16.93 Million USD | 96.41% |
| SCYNEXIS, Inc. | 15.08 Million USD | 95.968% |
| Harrow Health, Inc. | 190.5 Million USD | 99.681% |
| Biofrontera Inc. | 5.39 Million USD | 88.739% |
| DURECT Corporation | 20.74 Million USD | 97.069% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | 98.536% |
| ANI Pharmaceuticals, Inc. | 315.32 Million USD | 99.807% |
| OptiNose, Inc. | 131.74 Million USD | 99.539% |
| RedHill Biopharma Ltd. | 1.17 Million USD | 48.167% |
| Aquestive Therapeutics, Inc. | 98.82 Million USD | 99.385% |
| Cumberland Pharmaceuticals Inc. | 18.42 Million USD | 96.701% |
| SIGA Technologies, Inc. | 1.46 Million USD | 58.47% |
| Lifecore Biomedical, Inc. | 130.36 Million USD | 99.534% |
| Shineco, Inc. | 29.65 Million USD | 97.95% |
| Phibro Animal Health Corporation | 525.45 Million USD | 99.884% |
| Procaps Group S.A. | 285.93 Million USD | 99.787% |
| TherapeuticsMD, Inc. | 8 Million USD | 92.405% |
| Regencell Bioscience Holdings Limited | 59.8 Thousand USD | -916.603% |
| Viatris Inc. | 18.12 Billion USD | 99.997% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | 7.557% |
| Rockwell Medical, Inc. | 13.43 Million USD | 95.476% |
| Incannex Healthcare Limited | 373 Thousand USD | -63.003% |
| Aytu BioPharma, Inc. | 15.12 Million USD | 95.981% |
| Tilray Brands, Inc. | 387.31 Million USD | 99.843% |
| Collegium Pharmaceutical, Inc. | 674.28 Million USD | 99.91% |
| PetIQ, Inc. | 468.3 Million USD | 99.87% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 99.858% |
| Journey Medical Corporation | 17.73 Million USD | 96.571% |
| Alimera Sciences, Inc. | 67.39 Million USD | 99.098% |
| Petros Pharmaceuticals, Inc. | 8.27 Million USD | 92.654% |
| Assertio Holdings, Inc. | 40.91 Million USD | 98.514% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.08 Million USD | 44.102% |
| Embecta Corp. | 1.63 Billion USD | 99.963% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | 41.149% |
| Procaps Group, S.A. | 285.93 Million USD | 99.787% |
| PainReform Ltd. | 86 Thousand USD | -606.977% |
| Avadel Pharmaceuticals plc | 35.38 Million USD | 98.282% |
| Hempacco Co., Inc. | 13.72 Million USD | 95.57% |
| Talphera, Inc. | - USD | -Infinity% |
| Pacira BioSciences, Inc. | 586.04 Million USD | 99.896% |
| Alvotech | 1.07 Billion USD | 99.943% |
| Lantheus Holdings, Inc. | 616.94 Million USD | 99.901% |
| Kamada Ltd. | 8.74 Million USD | 93.051% |
| Indivior PLC | 281.6 Million USD | 99.784% |
| Currenc Group, Inc. | 31.94 Million USD | 98.097% |
| Evoke Pharma, Inc. | 5 Million USD | 87.84% |
| Flora Growth Corp. | 3.67 Million USD | 83.442% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | 41.149% |
| Evolus, Inc. | 126.54 Million USD | 99.52% |
| HUTCHMED (China) Limited | 86.13 Million USD | 99.294% |
| Amphastar Pharmaceuticals, Inc. | 623.64 Million USD | 99.903% |
| Akanda Corp. | 3.99 Million USD | 84.795% |